ArticleOncotarget2017
Suppression of microRNA-205-5p in human mesenchymal stem cells improves their therapeutic potential in treating diabetic foot disease.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Advances in the biological functions of miR‑205 in various diseases (Review).Molecular medicine reports · 2026Review
- Revolutionizing Diabetic Foot Ulcer Management: Exploring the Therapeutic Potential of Natural Products.Current pharmaceutical design · 2026Review
- Stem cell therapy: a promising frontier in modern medicine with a comprehensive overview of their biology and potential therapeutic applications in chronic non-healing cutaneous injuries.Inflammopharmacology · 2025Review
- Macrophages regulate healing-associated fibroblasts in diabetic wound.Molecular biology reports · 2024Article
- Effects of microRNAs on angiogenesis in diabetic wounds.Frontiers in medicine · 2023Review
- Non-coding RNAs: Role in diabetic foot and wound healing.World journal of diabetes · 2022Review
- Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- [Research advances on stem cell therapy for diabetic foot wounds].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Review
- Stem Cell-Based Therapy for Diabetic Foot Ulcers.Frontiers in cell and developmental biology · 2022Review
- The progress, prospects, and challenges of the use of non-coding RNA for diabetic wounds.Molecular therapy. Nucleic acids · 2021Review
- PlGF Reduction Compromises Angiogenesis in Diabetic Foot Disease Through Macrophages.Frontiers in immunology · 2021Article
- The Abnormal Expression of miR-205-5p, miR-195-5p, and VEGF-A in Human Cervical Cancer Is Related to the Treatment of Venous Thromboembolism.BioMed research international · 2020Article
- Article
- Mesenchymal stem cells rejuvenate cardiac muscle through regulating macrophage polarization.Aging · 2019Article
- MicroRNAs in diabetic wound healing: Pathophysiology and therapeutic opportunities.Trends in cardiovascular medicine · 2019Review
- Article
- Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression.Cancer biomarkers : section A of Disease markers · 2019Article
- Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Efficient Nonviral Transfection of Human Bone Marrow Mesenchymal Stromal Cells Shown Using Placental Growth Factor Overexpression.Stem cells international · 2018Article
- Augmentation of hypoxia-inducible factor-1-alpha in reinfused blood cells enhances diabetic ischemic wound closure in mice.Oncotarget · 2017Article
Corrections and comments
- Retraction · 2025-12-31Duplication of/in Image · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Plagiarism of Image ·
- Retracted
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a prevalent disease endangering human health, while diabetic foot disease (DF) is one of the most severe complications of diabetes. Mesenchymal stem cells (MSCs) have been used in DF treatment, taking advantage of the differentiation potential of MSCs into endothelial cells and their production and secretion of trophic factors like vascular endothelial growth factor (VEGF). Molecular modification of MSCs to improve their therapeutic effects has been recently applied in treating other diseases, but not yet in DF. Here, we found that micoRNA-205-5p (miR-205-5p) is expressed in human MSCs, and miR-205-5p inhibits protein translation of VEGF through its interaction with 3'-UTR of the VEGF mRNA. Expression of antisense of miR-205-5p (as-miR-205-5p) significantly increased both cellular and secreted VEGF by MSCs, which significantly improved the therapeutic effects of MSCs on DF-associated wound healing in diabetic NOD/SCID mice. Together, our data suggest that miR-205-5p suppression in MSCs may improve their therapeutic effects on DF, seemingly through augmentation of VEGF-mediated vascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.